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INTRODUCTION
Systemic sclerosis (SSc, scleroderma) is an autoimmune dis-
ease characterized by the accelerated accumulation of extra-
cellular matrix and by various immunologic abnormalities
(1). Serum autoantibodies are helpful markers because they
have been correlated with certain clinical features of SSc (2,
3). Of the various SSc-related antibodies, anti-RNA polyme-
rase (RNAP) antibodies are known to be SSc specific and to
be present in 4-33% of SSc patients (4-8). There are three
classes of RNAPs (RNAPs I, II, and III) (9) and anti-RNAP
I and III (I/III) antibodies have been detected exclusively in
SSc patients; moreover, the presence of these antibodies is
known to be associated with diffuse cutaneous involvement
and renal crisis (5, 6, 10, 11). Although the association bet-
ween scleroderma renal crisis and anti-RNAP I/III antibod-
ies has been reported in Caucasians and in the Japanese, no
such report has been issued in the Korean SSc population.
Furthermore, autoantibodies in Korean SSc patients show
several distinctive features; 1) no association between disease
subset and autoantibodies, such as, anti-topoisomerase I (anti-
topo I) or anticentromere antibody (ACA), 2) a much lower
prevalence of ACA in a limited subset (6.7-8.0% vs. 44% in
Caucasians and 37% in the Japanese), and 3) no significant
difference in the clinical characteristics of disease subsets, ex-
cept for more frequent musculoskeletal involvement in a lim-
ited subset (12-14). Here, we report for the first time a case
of renal crisis in a Korean SSc patient with serum anti-RNAP
I/III antibodies detected by radioimmunoprecipitation (5).  
CASE REPORT
A 65-yr-old female visited the Rheumatology Clinic due
to the thickening of hand and facial skin with digital pallor
and cyanosis on cold exposure, which had developed 2 months
previously. On the first visit to the clinic, her blood pressure
was 130/80 mmHg and physical examination revealed skin
thickening on the fingers of both hands, and on the right hand
dorsum and right forearm. She was diagnosed as having sys-
temic sclerosis of the limited cutaneous subset based on the
American Rheumatism Association preliminary criteria (15).
Laboratory data showed white blood cells at 8.39×109/L,
hemoglobin 12.1 g/dL, platelets 240×109/L, ESR 8 mm/hr
(normal range: 0-20), GOT 21U/L, GPT 18 U/L, total biliru-
bin 0.6 mg/dL, albumin 3.7 g/dL, BUN 11 mg/dL, and cre-
atinine 0.7 mg/dL. Antinuclear antibody was positive, but
ACA and anti-topo I were negative. Pulmonary function test-
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A Case of Renal Crisis in a Korean Scleroderma Patient with 
Anti-RNA polymerase I and III Antibodies
Scleroderma (SSc) renal crisis has been reported to be associated with anti-RNA
polymerase I and III (RNAP I/III) antibodies in Caucasians and the Japanese. How-
ever, no report is available for Korean SSc patients. Here, we describe the case of
a 65-yr-old female SSc patient who developed renal crisis and whose serum con-
tained anti-RNAP I/III antibodies. She was finally diagnosed as having diffuse cuta-
neous SSc based on skin thickening proximal to the elbows and knees. Sudden
hypertension, oliguria, and pulmonary edema were features of her renal crisis. Des-
pite the use of captopril and adequate blood pressure control, her renal function dete-
riorated. Subsequent renal biopsy findings showed severe fibrinoid necrosis with
luminal obliteration in interlobar arteries and arterioles consistent with SSc renal cri-
sis. Serum anti-RNAP I/III antibodies were detected by radioimmunoprecipitation.
This is the first report of a renal crisis in a Korean SSc patient with RNAP I/III anti-
bodies.  
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ing produced the following; forced vital capacity, 73%; forced
expiratory volume in 1 sec, 79%; and diffusing capacity of
carbon monoxide over volume of alveoli, 121%. High reso-
lution computed tomography of the lungs revealed old tuber-
culosis in the right lower lobe with pleural thickening and
calcifications without evidence of interstitial lung disease.
Prazosin 1 mg/day was administered for Raynaud’s phenome-
non and intermittent antihistamines for skin pruritus. Twen-
ty-two months after the diagnosis of limited SSc, her skin
thickening began to rapidly progress above elbows and knees,
and finally involved the trunk. Blood pressure was in the nor-
mal range. The diagnosis was converted to SSc of the diffuse
cutaneous subset and she was started on D-penicillamine 250
mg/day. A month later, she visited the emergency room due
to the sudden onset of facial edema and severe dyspnea. Her
blood pressure was 220/134 mmHg, heart rate 120 beats/
min, respiration rate 48/min, and body temperature 35℃.
She reported that the dyspnea had begun 10 days previously
and that her urine output had decreased markedly. A physi-
cal examination revealed facial and pre-tibial edema, and pul-
monary rales in the whole lung field. Laboratory data showed
hemoglobin at 9.9 g/dL, LDH 703 IU/L, total bilirubin 2.9
mg/dL, indirect bilirubin 1.8 mg/dL, and schistocytes with
polychromasia on peripheral blood smear, suggesting intra-
vascular hemolysis. Antineutrophil cytoplasmic antibody was
negative. Urinalysis and microscopic examination showed
mild albuminuria (1+by dipstick test), hematuria (≥100
red blood cells per high power field with dysmorphic red
blood cells >90%), and pyuria (20-29 white blood cells per
high power field). Urine culture grew no organisms. Azote-
mia was also detected with a BUN of 31 mg/dL and a crea-
tinine of 2.2 mg/dL. Her chest radiograph showed cardio-
megaly and bilateral hilar infiltrates consistent with pulmo-
nary edema. She was transferred to intensive care unit, intu-
bated, and assisted with a mechanical ventilator. Under a dia-
gnosis of scleroderma renal crisis, captopril was begun, but
failed to reverse a deteriorating renal function despite success-
ful blood pressure control within 2 days. Renal biopsy showed
severe fibrinoid necrosis with luminal obliteration in inter-
lobar arteries and arterioles, strongly suggesting scleroderma
renal crisis (Fig. 1). Immunofluorescence staining showed no
evidence of immune complex or autoantibody deposition.
Because scleroderma renal crisis has been reported to be asso-
ciated with anti-RNAP I or III antibodies, we tested whether
this patient had anti-RNAP antibodies in her serum. Indeed,
anti-RNAP I/III antibodies were detected by radioimmuno-
precipitation using 35S-methionine-labeled K 562 cells (Fig.
2). Hemodialysis was started and has been continued for 3
yr without renal recovery. 
DISCUSSION 
This is the first case report of scleroderma renal crisis with
the presence of RNAP I/III antibodies in the Korean popu-
lation. Renal crisis in this patient was diagnosed by acceler-
ated hypertension and acute renal failure with a typical renal
pathology. The presence of serum anti-RNAP antibodies was
detected by radioimmunoprecipitation. The clinical findings
in association with the presence of anti-RNAP I/III antibod-
ies in this case are consistent with previous reports of SSc pa-
tients (5, 6, 10, 11, 16, 17), with respect to; 1) renal crisis
in association with anti-RNAP I/III antibodies, 2) the pres-
ence of anti-RNAP I/III antibodies in a diffuse subset patient,
and 3) the absence of anti-topo I in the presence of anti-RNAP
I/III antibodies. 
Although not all SSc patients with anti-RNAP I/III anti-
bodies develop renal crisis, renal crisis occurs in anti-RNAP
I/III antibody positive patients much more frequently than
Fig. 1. Renal biopsy shows fibrinoid necrosis and intraluminal oblit-
eration of the interlobar artery. 
Fig. 2. Radioisotope
labeled subunits of
RNAP I (190 and 126
kDa) and III (155 and
138 kDa) were pre-
cipitated by the pati-
ent serum. The serum
of an SSc patient with
antibodies to all three
RNAPs (I, II, III) was
used as a reference. 
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in negative patients (5, 6, 11). Moreover, it is well known that
the early administration of angiotensin converting enzyme
(ACE) inhibitors can improve renal outcome. Therefore, know-
ing whether anti-RNAP I/III antibodies are present before
renal crisis onset should alert physicians to the possibility of
renal crisis and facilitate the initiation of prompt treatment. 
According to Steen et al. (18), 44% (24/55) of scleroderma
renal crisis patients who received ACE inhibitors, either died
or required permanent dialysis while 56% (31/55) of them
did not require dialysis at all or needed only transient dialy-
sis. The factors that were associated with poor renal outcome
were old age (>55 yr) (odds ratio, 12.28; p=0.002) and the
presence of congestive heart failure (odds ratio, 3.89; p=0.03).
This patient showed both factors and administration of cap-
topril failed to improve her renal function. The poor response
to ACE inhibitor in this patient suggests that her renal func-
tion had irreversibly deteriorated prior to initiation of medi-
cal treatment because she had symptoms of acute renal failure
for at least 10 days before she was treated.
RNAPs (RNAPs I, II, and III) are multimeric proteins that
are composed of 8-14 subunits of 10 to 220 kDa (9). The two
largest subunits are unique to each class and are readily dis-
tinguishable by their characteristic mobilities on SDS-poly-
acrylamide gel (6, 7). Because of the size and complexity of
RNAPs, it has proven difficult to develop methods for detect-
ing anti-RNAP antibodies that are applicable in a clinical
laboratory setting despite the potential benefit of knowledge
on the presence of anti-RNAP I/III antibodies. However,
recently, it was reported that anti-RNAP antibodies can be
detected reliably using an enzyme-linked immunosorbent
assay method (17, 19), which might help measure these anti-
bodies routinely in the near future.
In summary, we report a case of renal crisis in the presence
of anti-RNAP I/III antibodies in a Korean SSc patient of a
diffuse cutaneous subset. Further studies with a sufficient
number of patients are needed to confirm the association bet-
ween the presence of anti-RNAP I/III antibodies and clini-
cal features in the Korean population.  
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